Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial.
Nations KR, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D, Gertsik L, Johnstone J, Lee A, Pande Y, Ruigt G, Ereshefsky L. Nations KR, et al. Among authors: ereshefsky l. J Psychopharmacol. 2012 Dec;26(12):1525-39. doi: 10.1177/0269881112458728. Epub 2012 Sep 6. J Psychopharmacol. 2012. PMID: 22954616 Clinical Trial.
Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.
Nations KR, Bursi R, Dogterom P, Ereshefsky L, Gertsik L, Mant T, Schipper J. Nations KR, et al. Among authors: ereshefsky l. Drugs R D. 2012 Sep 1;12(3):127-39. doi: 10.2165/11634360-000000000-00000. Drugs R D. 2012. PMID: 22852579 Free PMC article. Clinical Trial.
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.
Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. Fava M, et al. Among authors: ereshefsky l. Mol Psychiatry. 2016 Oct;21(10):1372-80. doi: 10.1038/mp.2015.178. Epub 2015 Dec 8. Mol Psychiatry. 2016. PMID: 26643541 Free PMC article. Clinical Trial.
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.
Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. Fava M, et al. Among authors: ereshefsky l. Mol Psychiatry. 2016 Oct;21(10):1483-4. doi: 10.1038/mp.2016.140. Epub 2016 Aug 16. Mol Psychiatry. 2016. PMID: 27528461 Free PMC article. No abstract available.
Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders.
Cohen EA, Hassman HH, Ereshefsky L, Walling DP, Grindell VM, Keefe RSE, Wyka K, Horan WP. Cohen EA, et al. Among authors: ereshefsky l. Neuropsychopharmacology. 2021 Mar;46(4):844-850. doi: 10.1038/s41386-020-00911-5. Epub 2020 Nov 26. Neuropsychopharmacology. 2021. PMID: 33244149 Free PMC article. Clinical Trial.
Schizophrenia: how should we look at it?
Miller AL, Ereshefsky L. Miller AL, et al. Among authors: ereshefsky l. J Psychopharmacol. 1997;11(1):21-3; discussion 28. doi: 10.1177/026988119701100106. J Psychopharmacol. 1997. PMID: 9097887 No abstract available.
112 results